Equities
  • Price (EUR)1.37
  • Today's Change-0.005 / -0.36%
  • Shares traded281.00
  • 1 Year change-72.22%
  • Beta0.4311
Data delayed at least 15 minutes, as of Dec 05 2022 16:36 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

bioXXmed AG, formerly CytoTools AG, is a Germany-based holding company that invests in biotechnological or medical technology companies with equity or borrowed capital. The Company holds interests in research and development (R&D) companies DermaTools Biotech GmbH, which is active in the field of dermatology and urology, and CytoPharma GmbH, which is engaged in product development for cardiovascular diseases, cancer and other indications. bioXXmed AG manages the patent portfolio and coordinates the licensing for its subsidiaries. The product pipeline of disease modifying therapies based on the mechanisms of cell growth and programmed cell death, comprising small molecules and biologics across a range of disease indications, includes DermaPro, the Company's lead product indicated for diabetic and venous foot ulcers in phase III of clinical trials, as well as Utisept, an urological medical device for flushing the bladder in urinary tract infections.

  • Revenue in EUR (TTM)44.48k
  • Net income in EUR-3.94m
  • Incorporated2006
  • Employees0.00
  • Location
    bioXXmed AGRiedstrasse 2DARMSTADT 64295GermanyDEU
  • Phone+49 61 519515812
  • Fax+49 61 519515813
  • Websitehttps://cytotools.de
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Peptonic Medical AB3.32m-6.76m6.34m----1.21--1.91-0.3723-0.37230.17580.23450.41881.043.39---85.26-38.78-113.84-45.5560.91---203.61-223.580.5254-38.840.2223---10.10---115.39---16.66--
Abingdon Health PLC3.31m-24.80m6.39m130.00--0.8515--1.93-0.1747-0.17470.02330.05290.12331.530.318221,807.69-92.45---142.14---126.70---749.98--1.96-193.120.166---75.60---204.92------
Cizzle Biotechnology Holdings PLC0.00-1.25m6.64m67.00--1.70-----0.0115-0.01150.000.00990.00-------51.90-106.45-56.19-281.32--27.99---2,362.46----0.00-------1,181.37------
Midatech Pharma PLC752.19k-6.26m6.72m20.00--0.7692--8.93-0.0547-0.05470.00660.07610.0718--0.488332,250.00-59.78-40.54-86.07-49.01-----832.09-1,301.64----0.0869--68.51-15.2675.39---25.19--
PCI Biotech Holding ASA461.70k-7.14m7.03m17.00--1.14--15.22-1.97-1.970.12731.700.0416--0.5862279,529.40-64.25-33.17-72.79-36.55-----1,545.58-762.80----0.0221---14.86-9.75-22.36------
Inno-Gene SA5.08m-34.71k7.03m27.00--3.7090.521.38-0.0285-0.02854.171.561.6620.666.90---1.138.84-1.7711.3135.1750.16-0.682819.612.552.570.03080.00538.6644.97290.56--35.79--
Bioextrax AB publ50.17k-1.45m7.06m----3.11--140.77-1.01-1.010.03470.9710.0332--3.26---95.97---123.03---86.52---2,890.40-----22,539.960.00--1,166.12---89.02------
bioXXmed AG44.48k-3.94m7.06m0.00--0.3245--158.81-0.9268-0.92680.00964.240.002--1.22---17.92-11.61-18.18-12.35-----8,853.06-4,674.96---0.54750.0189--23.97---120.69------
Redwood Pharma AB0.00-1.08m7.12m----3.24-----0.1932-0.19320.000.1280.00-------71.61-118.96-92.75-172.86-----------391,109.000.00-------43.48------
Theranexus SA0.00-7.72m7.15m19.00--0.9698-----1.46-1.460.001.800.00----0.00-44.28-31.66-47.93-35.11-----------20.070.3865-------69.89---2.28--
Genxone SA3.92m1.12m7.33m--6.571.765.081.871.581.585.575.900.91627.1035.94--26.05--27.00--53.78--28.43--17.93--0.00--13.29--22.57------
Veg of Lund AB (publ)292.09k-4.08m7.41m--------25.37-2.63-2.630.1844-0.18360.14470.82457.59---201.98-138.73-365.70-212.6422.6934.56-1,395.44-936.480.3747-157.951.57--118.61---29.46------
Alzinova AB0.00-993.41k7.51m----0.7409-----0.4388-0.43880.003.400.00-------10.34-8.30-10.66-8.62-----------476.840.00-------16.19--28.46--
Theravet SA-100.00bn-100.00bn7.63m--------------------------------------------------------------
Aptahem AB26.93k-1.11m7.71m----1.07--286.43-0.0286-0.02860.00220.3750.0048--0.0867---19.85-62.97-21.05-69.82860.07---4,129.94-1,200,317.00---605,035.500.00-------17.30------
Data as of Dec 05 2022. Currency figures normalised to bioXXmed AG's reporting currency: Euro EUR
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.